Influence of Neoadjuvant Chemotherapy on Radiotherapy for Breast Cancer
Influence of Neoadjuvant Chemotherapy on Radiotherapy for Breast Cancer
复制标题
DOI：
10.1245/s10434-015-4402-x
复制
发表时间：
2015-05-01
影响因子：
3.7
通讯作者：
Buchholz, Thomas A.
中科院分区：
文献类型：
--
作者：
Garg, Amit K.;Buchholz, Thomas A.
新辅助化疗是局部晚期可手术乳腺癌患者的标准治疗选择，并越来越多地用于早期乳腺癌。新辅助化疗的最初随机试验确立了在存活率方面与辅助化疗相同，但它们也证明了乳房保留率的提高，以及在对化疗有良好反应后改变局部区域复发风险的能力。高质量的非随机数据有助于在新辅助化疗和保乳手术或乳房切除术后定制放射治疗建议。正在进行的3期随机试验(NSABP B-51/RTOG 1304)的结果将有助于阐明局部区域放射治疗对于在新辅助化疗后结节阴性的临床N1疾病患者的价值。
Neoadjuvant chemotherapy is a standard treatment option for patients with locally advanced operable breast cancer and is increasingly used in early breast cancer. Initial randomized trials of neoadjuvant chemotherapy established equivalency to adjuvant chemotherapy in terms of survival, but they also demonstrated improved rates of breast conservation and the ability to modify the risk of locoregional recurrence after a favorable response to chemotherapy. High-quality nonrandomized data have helped to tailor radiotherapy treatment recommendations after neoadjuvant chemotherapy and breast-conserving surgery or mastectomy. Results from an ongoing phase 3 randomized trial (NSABP B-51/RTOG 1304) will help to clarify the value of locoregional radiotherapy for patients with clinical N1 disease that becomes node negative after neoadjuvant chemotherapy.